Corticosteroid prescription in children with respiratory symptoms: A real-life study

Main Article Content

Remedios Cárdenas Contreras
Alicia Habernau Mena
Elisa Haroun Díaz
Javier Ruíz Hornillos
Margarita Tomás Pérez
Rafael Pineda Pineda
Elena Mederos Luis
Maria Ángeles González Labrador
Ana Rosadoi
Silvia Sánchez García
Eloísa Rubio Pérez
Ignacio Salamanca de la Cueva

Keywords

children, asthma, corticosteroid overuse

Abstract

Asthma is one of the most common childhood diseases. Most children respond to low doses of corticosteroids and/or anti-leukotrienes. However, a small percentage remain symptomatic. They require high doses of inhaled corticosteroids (ICS) and anti-leukotrienes, sometimes with long-acting bronchodilators (LABA) and occasionally systemic corticosteroids (SC). However, we frequently observe that the only treatment they receive for exacerbations is short-acting beta-agonists (SABA) and oral corticosteroids (OC) without adding ICS as a maintenance treatment to prevent new episodes. This leads to frequent exacerbations, airflow limitation, and significant alterations in the quality of life. In addition, this results in high resource consumption, frequent emergency room visits, and school absenteeism, leading to absence from work for caregivers. A descriptive, retrospective, observational, and multicenter study was carried out on patients under 12 years of age, who attended pediatric allergy consultations for the first time. The main objective was to determine the consumption of SCs because of respiratory exacerbations in the year before the first consultation. Data were obtained from 144 children, 58.3% male, with a median age of 5 years. It was found that during the year before attending our clinic, 70% had perennial symptoms and were only prescribed with salbutamol on demand when they presented with respiratory symptoms. They had not been prescribed with ICS or anti-leukotrienes. They required attention in the emergency room of their nearest health center or hospital on an average of three times per year. During these exacerbations, almost 75% received SCs(prednisolone), with an average of 2.6 annual cycles (0–12) prescribed in more than half of the cases in the emergency room. In over 80% of the cases, the effects of SC abuse were not previously monitored. The overuse of SC in atopic children with respiratory symptoms was confirmed in our group, which requires considering behavioral changes.

Abstract 92 | PDF Downloads 193 HTML Downloads 0 XML Downloads 1

References

1 The Global Asthma Report 2014. http://www.theunion.org/whatwe-do/publications/technical/english/Global_Asthma_Report_2014.pdf.

2 World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases.

3 Carvajal-Urueña I, García-Marcos L, Busquets-Monge R, et al. Variaciones geográficas en la prevalencia de síntomas de asma en los niños y adolescentes españoles. International Study of Asthma and Allergies in Childhood (ISAAC) fase III España [Geographic variation in the prevalence of asthma symptoms in Spanish children and adolescents. International Study of Asthma and Allergies in Childhood (ISAAC) Phase 3, Spain]. Arch Bronconeumol. 2005;41(12):659–666. 10.1016/S1579-2129(06)60333-9

4 Guía GEMA 5.4. www.semg.es/index.php/consensos-guias-y-protocolos/427-gema-5-4-guia-espanola-para-el-manejo-del-asma.

5 Bercedo-Sanz A, Martínez-Torres A, González-Díaz C, López-Silvarrey Varela A, Pellegrini-Belinchón FJ, Aguinaga-Ontoso I, et al. Prevalence and temporal evolution of asthma symptoms in Spain. Global Asthma Network (GAN) study. An Pediatr. 2022;97:161–7. 10.1016/j.anpede.2021.10.005

6 Pearce N, Ait-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: Phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007; 62: 758–66. 10.1136/thx.2006.070169

7 Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK et al. ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733–43. 10.1016/S0140-6736(06)69283-0

8 Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma [published correction appears in Eur Respir J. 2014 Apr;43(4):1216. Dosage error in article text] [published correction appears in Eur Respir J. 2018 Jul 27;52(1)]. Eur Respir J. 2014;43(2):343–373.

9 Lang A, Carlsen KH, Haaland G, et al. Severe asthma in childhood: Assessed in 10 year old in a birth cohort study. Allergy. 2008;63:1054–60. 10.1111/j.1398-9995.2008.01672.x

10 Blanc FX, Postel-Vinay N, Boucot I, De Blic J, Scheinmann P. Etude AIRE: Analyse des données recueillies chez 753 enfants asthmatiques en Europe [The AIRE Study: Data analysis of 753 European children with asthma]. Rev Mal Respir. 2002 Oct; 19(5 Pt 1):585–92. French. PMid: 12473945.

11 Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010; 126:926–38. 10.1016/j.jaci.2010.07.019

12 Brand PL, Baraldi E, Bisgaard H, et al. Definition, assessment and treatment of wheezing disorders in preschool children: An evidence-based approach. Eur Respir J. 2008;32:1096–110. 10.1183/09031936.00002108

13 Marcone DN, Ricarte C, Videla C, et al. Rinovirus. Frecuencia en niños con infección respiratoria aguda, no internados. Medicina (B Aires). 2012;72:28.

14 Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J. 2008;32:545–54. 10.1183/09031936.00155307

15 Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: The asthma insights and reality in Europe (AIRE) study. EurResp J. 2000;16:802–7. 10.1183/09031936.00.16580200

16 Suárez-Castañón C, Modroño-Riaño G, Solís-Sánchez G. Variability and suitability of anti-asmathic treatment in pediatric primary health care. Aten Primaria. 2017;49:263–270. 10.1016/j.aprim.2016.07.001

17 Ángeles-Garay U, Becerril-Ángeles MH, Morán-Sotelo D, Ruiz-Betancourt BS, Acosta-Cazares B. Asthma control and quality of life of asthmatic children and their caregivers. Rev Med Inst Mex Seguro Soc. 2020;58:548–556.

18 Quirce S, Plaza V, Picado C, Vennera M, Casafont J. Prevalence of uncontrolled severe persistent asthma in pneumology and allergy hospital units in Spain. J. Investig. Allergol. Clin. Immunol. 2011;21(6): 466–471.

19 Plaza V (Coord). Guía Española para el Manejo del Asma 5.3 (GEMA5.3). Madrid: Luzán 5;2015.

20 Beckhaus AA, Riutort MC, Castro-Rodriguez JA. Inhaled versus systemic corticosteroids for acute asthma in children. A systematic review. Pediatr Pulmonol. 2014 Apr. 49(4):326–34. 10.1002/ppul.22846. Epub 2013 Aug 8. PMid: 23929666.

21 Bleecker ER, Al-Ahmad M, Bjermer L, Caminati M, Canonica GW, Kaplan A, et al. Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group. World Allergy Organ J. 2022. 10;15(12):100726. 10.1016/j.waojou.2022.100726. PMid:365824024; PMCID: PMC9761384.

22 Casale TB, Corbridge T, Germain G, Laliberté F, MacKnight SD, Boudreau J, et al. Real-world association between systemic corticosteroid exposure and complications in US patients with severe asthma. Allergy Asthma Clin Immunol. 2024 Mar. 26;20(1):25. 10.1186/s13223-024-00882-y. PMid: 38532489; PMCID: PMC10964513.

23 de Benedictis FM, Carloni I, Guidi R. Safety of anti-inflammatory drugs in children with asthma. Curr Opin Allergy Clin Immunol. 2021 Apr. 1;21(2):144–150. 10.1097/ACI.0000000000000730. PMid: 33470588.

24 Paddy McCrossan , Michael D Shields, James C McElnay. Medication adherence in children with asthma. Patient preference and adherence. 2024.18: 555–564. 10.2147/PPA.S445534

25 Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Available at: https://ginasthma.org/2024-report/

26 Papadopolus et al. Type 2 Inflammation and asthma in children: A narrative review. Allergy Clin. Immunol. Pract. 2024;12:2310–24. 10.1016/j.jaip.2024.06.010